|
"poon r t p"的相關文件
顯示項目 11-17 / 17 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-03-15T07:44:47Z |
Recent advances in the prevention of hepatocellular carcinoma recurrence
|
LI-CHUN LU; Cheng A.-L.; Poon R.T.P. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Chia-Chi Lin; Akimov M; Ghebremariam S; Hong D; Poon R.T.P; Azaro A; Lim W.T; Bauer T.M; Nam D.-H; Schuler M; Su W.-C; Bang Y.-J; Zhao S; Giovannini M; Ma B. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |
| 臺大學術典藏 |
2020-02-19T09:33:43Z |
Surgery for intermediate and advanced hepatocellular carcinoma: A consensus report from the 5th Asia-pacific primary liver cancer expert meeting (apple 2014)
|
MING-CHIH HO; Hasegawa K.; Chen X.-P.; Nagano H.; Lee Y.-J.; Chau G.-Y.; Zhou J.; Wang C.-C.; Choi Y.R.; Poon R.T.-P.; Kokudo N. |
| 國立成功大學 |
2020 |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang, Y.-J.;Su, W.-C.;Schuler, M.;Nam, D.-H.;Lim, W.T.;Bauer, T.M.;Azaro, Azaro A.;Poon, R.T.P.;Hong, D.;Lin, C.-C.;Akimov, M.;Ghebremariam, S.;Zhao, S.;Giovannini, M.;Ma, B. |
| 臺大學術典藏 |
2018-09-10T08:13:48Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata, M.;Lesmana, L.A.;Tateishi, R.;Chen, P.-J.;Lin, S.-M.;Yoshida, H.;Kudo, M.;Lee, J.M.;Choi, B.I.;Poon, R.T.P.;Shiina, S.;Cheng, A.L.;Jia, J.-D.;Obi, S.;Han, K.H.;Jafri, W.;Chow, P.;Lim, S.G.;Chawla, Y.K.;Budihusodo, U.;Gani, R.A.;Lesmana, C.R.;Putranto, T.A.;Liaw, Y.F.;Sarin, S.K.; PEI-JER CHEN; ANN-LII CHENG |
| 國立成功大學 |
2012-03 |
A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
|
Yau, T.; Yen, C. -J.; Chen, P. -J.; Chau, Y.; Lencioni, R.; Kallender, H.; Ottesen, L. H.; Poon, R. T. -P. |
顯示項目 11-17 / 17 (共1頁)
1
每頁顯示[10|25|50]項目
|
